Global Aneurysm Therapeutics Market Size By Type (Medicine, Surgery), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Aneurysm Therapeutics Market was valued at USD 3.6 billion in 2023 and is projected to reach USD 6.4 billion by 2031, expanding at a CAGR of 7.3% from 2023 to 2031. The market's growth is driven by the rising prevalence of aneurysms, increasing awareness of early diagnosis, and advancements in endovascular treatment techniques. Aneurysm therapeutics encompass a wide range of drug therapies and minimally invasive surgical procedures used to treat aneurysms in various parts of the body, such as cerebral, aortic, and peripheral arteries.

Drivers

1. Rising Prevalence of Aneurysms:

An increase in the incidence of aneurysms, particularly aortic and cerebral, is propelling demand for therapeutic options. Aging populations and lifestyle factors such as smoking and hypertension are key contributors to this trend.

2. Advancements in Endovascular Procedures:

Minimally invasive techniques like coil embolization and stent grafts have significantly improved treatment outcomes and recovery times, thereby accelerating their adoption globally.

3. Increased Healthcare Expenditure and Diagnostic Imaging Access:

Improved access to advanced imaging modalities such as CT and MRI scans enables early aneurysm detection, increasing patient survival and demand for therapeutics.

Restraints

1. High Cost of Treatment:

Endovascular and surgical interventions for aneurysm management are expensive, often limiting access in low-income regions.

2. Risks and Complications Associated with Invasive Procedures:

Despite advancements, complications such as infections, device failures, and post-surgical issues remain, affecting patient and provider confidence in some treatment modalities.

Opportunity

1. Emerging Markets and Unmet Medical Needs:

The market presents significant opportunities in emerging economies where the awareness and infrastructure for aneurysm treatment are steadily improving.

2. Development of Drug-Based Therapies:

Ongoing clinical trials and R&D focusing on pharmacological treatments for aneurysm stabilization offer potential for non-invasive therapeutic alternatives.

Market by System Type Insights

Cerebral Aneurysm Therapeutics held the largest share of the market in 2023 due to the high prevalence and critical nature of intracranial aneurysms. Treatments include endovascular coiling and surgical clipping.

Aortic Aneurysm Therapeutics is expected to witness the fastest growth rate during the forecast period, driven by rising cases of abdominal and thoracic aortic aneurysms, especially among the elderly population.

Market by End-use Insights

Hospitals accounted for the largest market share in 2023, supported by the availability of multidisciplinary care and emergency response systems.

Specialty Clinics are expected to grow at a robust pace as outpatient procedures become more common and advanced technologies become accessible to smaller healthcare settings.

Market by Regional Insights

North America led the market in 2023, backed by advanced healthcare systems, higher awareness, and a strong presence of leading medical device companies.

Asia-Pacific is projected to register the highest CAGR through 2031, driven by improving healthcare infrastructure, rising awareness, and increasing geriatric populations in countries such as China and India.

Competitive Scenario

Key players operating in the global aneurysm therapeutics market include:

Medtronic plc

Johnson & Johnson (DePuy Synthes)

MicroVention, Inc. (Terumo Corporation)

Stryker Corporation

Penumbra, Inc.

Boston Scientific Corporation

Endologix LLC

Cordis (Cardinal Health)

These companies are investing in clinical research, product innovation, and strategic collaborations to expand their therapeutic portfolios and global presence.

Scope of Work – Global Aneurysm Therapeutics Market

Report Metric Details

Market Size (2023) USD 3.6 billion

Projected Market Size (2031) USD 6.4 billion

CAGR (2023–2031) 7.3%

Market Segments By System Type (Cerebral, Aortic, Peripheral), By End-use (Hospitals, Specialty Clinics), By Region

Growth Drivers Rising prevalence of aneurysms, technological advancements in treatment, improved diagnostic access

Opportunities Growth in emerging markets, non-invasive drug-based therapies

Key Market Developments

2023: Medtronic plc launched a next-generation flow diverter device for treating intracranial aneurysms, improving device safety and efficacy.

2024: Stryker Corporation acquired a startup specializing in minimally invasive aortic aneurysm repair, enhancing its vascular solutions portfolio.

2025: Boston Scientific announced clinical trial results supporting the use of bioresorbable coils in cerebral aneurysm treatment, opening avenues for safer long-term outcomes.

FAQs

1) What is the current market size of the Global Aneurysm Therapeutics Market?

The market was valued at USD 3.6 billion in 2023.

2) What is the major growth driver of the Global Aneurysm Therapeutics Market?

The primary growth driver is the rising prevalence of aneurysms and advancements in endovascular treatment techniques.

3) Which is the largest region during the forecast period in the Global Aneurysm Therapeutics Market?

North America held the largest market share in 2023 and is expected to maintain its dominance.

4) Which segment accounted for the largest market share in the Global Aneurysm Therapeutics Market?

Cerebral Aneurysm Therapeutics held the largest market share in 2023.

5) Who are the key market players in the Global Aneurysm Therapeutics Market?

Key players include Medtronic plc, Johnson & Johnson, MicroVention, Stryker, Penumbra, and Boston Scientific.